Met Life Investment Management, LLC Cara Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

  • $17.1 Billion
  • Q3 2024

Shares

37 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Apr 29, 2024
BUY
$2.83 - $4.94 $57,038 - $99,565
20,155 New
20,155 $57,000
Q1 2023

May 09, 2024
BUY
$4.89 - $12.27 $98,557 - $247,301
20,155 New
20,155 $99 Million
Q1 2023

May 15, 2023
SELL
$4.89 - $12.27 $32,401 - $81,301
-6,626 Reduced 24.74%
20,155 $98,000
Q4 2022

Jun 14, 2023
BUY
$8.88 - $12.77 $58,838 - $84,614
6,626 Added 32.88%
26,781 $287,000
Q3 2022

May 10, 2024
BUY
$8.24 - $12.56 $26,293 - $40,078
3,191 Added 13.53%
26,781 $250,000
Q3 2022

Jun 14, 2023
BUY
$8.24 - $12.56 $54,598 - $83,222
6,626 Added 32.88%
26,781 $250,000
Q3 2022

Mar 22, 2023
BUY
$8.24 - $12.56 $26,293 - $40,078
3,191 Added 13.53%
26,781 $250,000
Q3 2022

Nov 14, 2022
BUY
$8.24 - $12.56 $26,293 - $40,078
3,191 Added 13.53%
26,781 $251,000
Q2 2022

May 10, 2024
SELL
$7.45 - $13.84 $27,483 - $51,055
-3,689 Reduced 13.52%
23,590 $215,000
Q2 2022

Jun 20, 2023
BUY
$7.45 - $13.84 $25,590 - $47,540
3,435 Added 17.04%
23,590 $215,000
Q2 2022

Mar 22, 2023
SELL
$7.45 - $13.84 $27,483 - $51,055
-3,689 Reduced 13.52%
23,590 $215,000
Q2 2022

Aug 11, 2022
SELL
$7.45 - $13.84 $27,483 - $51,055
-3,689 Reduced 13.52%
23,590 $215,000
Q1 2022

May 10, 2024
BUY
$9.94 - $12.65 $271,153 - $345,079
27,279 New
27,279 $331,000
Q1 2022

Jun 20, 2023
BUY
$9.94 - $12.65 $70,812 - $90,118
7,124 Added 35.35%
27,279 $331,000
Q1 2022

Mar 22, 2023
BUY
$9.94 - $12.65 $90,155 - $114,735
9,070 Added 49.81%
27,279 $331,000
Q1 2022

May 12, 2022
BUY
$9.94 - $12.65 $90,155 - $114,735
9,070 Added 49.81%
27,279 $331,000
Q4 2021

Jun 21, 2023
SELL
$11.99 - $18.14 $23,332 - $35,300
-1,946 Reduced 9.66%
18,209 $221,000
Q3 2021

Jun 21, 2023
SELL
$11.55 - $16.06 $22,476 - $31,252
-1,946 Reduced 9.66%
18,209 $281,000
Q2 2021

Jun 21, 2023
SELL
$12.38 - $29.19 $24,091 - $56,803
-1,946 Reduced 9.66%
18,209 $259,000
Q1 2021

May 17, 2024
BUY
$15.07 - $21.71 $274,409 - $395,317
18,209 New
18,209 $395,000
Q1 2021

Jun 26, 2023
SELL
$15.07 - $21.71 $29,326 - $42,247
-1,946 Reduced 9.66%
18,209 $395 Million
Q4 2020

Jun 22, 2023
SELL
$12.72 - $16.16 $24,753 - $31,447
-1,946 Reduced 9.66%
18,209 $275,000
Q3 2020

Jun 26, 2023
SELL
$12.34 - $17.92 $24,013 - $34,872
-1,946 Reduced 9.66%
18,209 $231,000
Q2 2020

May 24, 2024
BUY
$12.39 - $17.33 $225,609 - $315,561
18,209 New
18,209 $311 Million
Q2 2020

Jun 26, 2023
SELL
$12.39 - $17.33 $24,110 - $33,724
-1,946 Reduced 9.66%
18,209 $311,000
Q1 2020

Jul 12, 2023
SELL
$9.12 - $17.78 $17,747 - $34,599
-1,946 Reduced 9.66%
18,209 $240,000
Q4 2019

Jul 12, 2023
SELL
$16.11 - $25.98 $31,350 - $50,557
-1,946 Reduced 9.66%
18,209 $293,000
Q3 2019

Jul 12, 2023
SELL
$18.28 - $26.91 $35,572 - $52,366
-1,946 Reduced 9.66%
18,209 $332,000
Q3 2019

Mar 22, 2023
BUY
$18.28 - $26.91 $46,193 - $68,001
2,527 Added 16.11%
18,209 $332,000
Q3 2019

Nov 14, 2019
BUY
$18.28 - $26.91 $46,193 - $68,001
2,527 Added 16.11%
18,209 $333,000
Q2 2019

Jul 12, 2023
SELL
$17.68 - $21.57 $79,082 - $96,482
-4,473 Reduced 22.19%
15,682 $337,000
Q1 2019

Jul 13, 2023
SELL
$14.41 - $19.64 $64,455 - $87,849
-4,473 Reduced 22.19%
15,682 $307,000
Q4 2018

Jul 13, 2023
SELL
$12.45 - $23.47 $55,688 - $104,981
-4,473 Reduced 22.19%
15,682 $203,000
Q4 2018

Mar 22, 2023
SELL
$12.45 - $23.47 $138,182 - $260,493
-11,099 Reduced 41.44%
15,682 $203,000
Q4 2018

Feb 14, 2019
BUY
$12.45 - $23.47 $195,240 - $368,056
15,682 New
15,682 $204,000
Q3 2018

Nov 14, 2018
SELL
$17.57 - $23.95 $201,492 - $274,658
-11,468 Closed
0 $0
Q4 2017

Feb 15, 2018
BUY
$11.86 - $14.08 $136,010 - $161,469
11,468
11,468 $140,000

Others Institutions Holding CARA

# of Institutions
71
Shares Held
12.8M
Call Options Held
0
Put Options Held
0
View Full List

About Cara Therapeutics, Inc.

CARA Quotes by TradingView
  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $247M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email